Randomised comparison of Nobori™, biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial
Bernard Chevalier*1, MD; Patrick W. Serruys2, MD, PhD, FACC, FESC; Sigmund Silber3, MD, PhD, FESC; Eulogio Garcia4, MD; Harry Suryapranata5, MD, PhD, FACC, FESC; Karl Hauptmann6, MD; William Wijns7, MD, PhD, FESC; Gerhard Schuler8, MD; Farzin Fath-Ordoubadi9, BSc, MB BCh, MRCP; Stephen Worthley10, MBBS, PhD, FRACP; Leif Thuesen11, MD; Ian Meredith12, MBBS, PhD, FRACP; Marco Bressers13, MSc; Hirofumi Nagai14, MD, Dragica Paunovic15, MD; for the Nobori 1 Clinical Investigators
1. Centre Cardiologique du Nord, Saint-Denis, France; 2. Erasmus MC, Rotterdam, The Netherlands; 3. Kardiologische Gemeinschaftspraxis und HKL, Munich, Germany; 4. Gregorio Marañón, Madrid, Spain; 5. Isala Clinic, Zwolle, The Netherlands; 6. Krankenhaus d
Background: We studied the Nobori™ coronary stent coated with a bioabsorbable polymer and the anti-proliferative agent Biolimus A9 which may reduce neointimal formation.